Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare genetic condition that causes children to age at roughly seven times the normal rate. It occurs in about 1 in every 4 million births, and approximately 400 children and young adults worldwide are currently living with it. The average life expectancy is 14.6 years, with cardiovascular disease responsible for the vast majority of deaths.
What Causes Progeria
Progeria results from a single-letter change in a gene called LMNA, which provides instructions for building a protein that forms the structural scaffolding inside every cell’s nucleus. Think of this scaffolding like the frame of a tent: it keeps the nucleus in shape and helps it function properly. The specific mutation activates a faulty editing instruction in the gene, producing a shortened, defective version of the protein known as progerin.
Progerin is missing 50 of its normal building blocks and carries a permanent chemical tag that causes it to stick to the inner wall of the nucleus. As progerin accumulates, it warps the nucleus, disrupts how cells divide, and interferes with the signaling pathways that stem cells use to maintain and repair tissues. The higher the ratio of progerin to the normal protein in a child’s cells, the more severe the disease tends to be.
The mutation is almost always a new, spontaneous event rather than something inherited from a parent. It is not linked to anything parents did or were exposed to during pregnancy.
How Progeria Appears in Infancy
Babies with HGPS typically look healthy at birth and have a normal birth weight. The first signs emerge within the first year of life: growth slows dramatically, subcutaneous fat begins to disappear, and hair starts to thin. By the time a child reaches two, physical features are usually unmistakable.
Partial hair loss during the first year progresses to complete baldness, often including eyebrows and eyelashes. Skin changes are present in all affected children by age two, appearing as tight, thickened, or rippled patches. Small dimple-like outpouchings sometimes develop over the lower abdomen and upper thighs, along with irregular patches of lighter or darker skin.
Growth failure is profound. Both height and weight drop below the 3rd percentile for age, with weight falling disproportionately low relative to height. Children develop a characteristic appearance: a large head relative to a small face, prominent eyes, a small jaw, and a narrow nose. Their voices are high-pitched, and their nails become thin and fragile.
Skeletal and Joint Problems
Progeria takes a significant toll on the skeleton. Children develop a wide-legged “horse-riding” stance caused by hip abnormalities, and hip dislocations are possible. The collarbones and the small bones of the fingers gradually lose density and shrink through a process of bone resorption. Joint contractures, where joints stiffen and lose their full range of motion, worsen progressively over time. The upper chest narrows, and osteoporosis develops with an irregular pattern of bone mineral loss throughout the skull and long bones.
Cardiovascular Disease in Children With HGPS
Heart and blood vessel disease is the defining threat in progeria and the cause of death in roughly 80% of cases. The arteries of children with HGPS develop severe atherosclerosis, the same plaque buildup that causes heart attacks in older adults, but decades earlier. One study found that 100% of assessed patients had thickening in the walls of the carotid arteries.
Cardiovascular events generally do not appear before age five, but from that point the progression is relentless. Diastolic dysfunction, where the heart struggles to relax and fill properly between beats, is the most common cardiac abnormality. As children reach their teenage years, more serious problems emerge: thickening of the heart muscle, weakened pumping ability, and valve disease. Children gradually develop shortness of breath from heart failure or experience strokes caused by blocked blood flow to the brain. Heart failure and heart attacks account for 80% of deaths, with stroke responsible for another 3%.
How Progeria Is Diagnosed
Diagnosis usually begins when a pediatrician notices the combination of severe growth failure, hair loss, and characteristic skin changes during the first one to two years of life. No single physical finding is unique to progeria, but the pattern together is distinctive. Confirmation requires genetic testing that identifies the specific LMNA mutation. Because the condition is so rare, there is often a delay between the first symptoms and a definitive diagnosis.
Intellectual development and cognitive ability are normal in children with HGPS. The aging process affects the body’s connective tissues, bones, and blood vessels, not the brain.
Treatment With Lonafarnib
In 2020, the FDA approved the first treatment specifically for progeria: a medication sold under the brand name Zokinvy (lonafarnib). It works by blocking the chemical process that attaches progerin to the inner wall of the cell nucleus. Without that attachment, less progerin accumulates, and cells function more normally.
The survival benefit is meaningful. In clinical follow-up spanning 11 years, treated patients lived an average of 2.5 years longer than untreated patients, and their risk of death was reduced by 60%. The medication is taken as a capsule twice daily with meals. Gastrointestinal side effects are common, so the dose is started lower and increased after four months.
Lonafarnib does not cure progeria. It slows the disease but does not stop it, meaning children still develop cardiovascular complications and other features of the syndrome over time. Supportive care, including physical therapy for joint stiffness and careful cardiac monitoring, remains an important part of management.
Gene Editing as a Potential Future Therapy
Researchers at the National Human Genome Research Institute have used a technique called base editing to correct the progeria mutation in mouse models. Base editing swaps a single DNA letter for another without cutting the DNA strand, making it more precise than older gene-editing approaches. In lab dishes, the treatment corrected the mutation in 90% of patient-derived cells. When delivered as a single intravenous injection to newborn mice carrying the progeria mutation, treated animals lived nearly 1.5 years compared to seven months for untreated mice, roughly doubling their lifespan. Translating this approach to humans remains an active area of work, with key safety and delivery questions still being addressed in animal models.